搜索
NewAmsterdam Pharma Company NV
NAMS添加自选
27.790USD
-0.670-2.35%
收盘 07-31 16:00（美东）报价延迟15分钟
3.25B总市值
亏损市盈率 TTM
关于 NewAmsterdam Pharma Company NV 公司
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV简介
公司代码NAMS
公司名称NewAmsterdam Pharma Company NV
上市日期Nov 23, 2022
CEODavidson (Michael Harvey)
员工数量68
证券类型Ordinary Share
年结日Nov 23
公司地址Gooimeer 2-35
城市NAARDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Netherlands
邮编1411 DC
电话31352062971
网址https://ir.newamsterdampharma.com/
公司代码NAMS
上市日期Nov 23, 2022
CEODavidson (Michael Harvey)
NewAmsterdam Pharma Company NV公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
常见问题
NewAmsterdam Pharma Company NV的前五大股东是谁？
NewAmsterdam Pharma Company NV 的前五大股东如下：Mr. John W. Smither
有多少机构持有NewAmsterdam Pharma Company NV(NAMS)的股份？
截至2026Q1，共有366家机构持有NewAmsterdam Pharma Company NV的股份，合计持有的股份价值约为128.70M，占公司总股份的110.09%。与2025Q4相比，机构持股有所增加，增幅为2432976.00。